Inovio Pharmaceuticals Price to Free Cash Flow Ratio 2006-2021 | INO

Historical price to free cash flow ratio values for Inovio Pharmaceuticals (INO) since 2006. For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Inovio Pharmaceuticals Price to Free Cash Flow Ratio Historical Data
Date Stock Price TTM FCF per Share Price to FCF Ratio
2021-10-15 7.02 0.00
2021-06-30 9.27 $-1.45 0.00
2021-03-31 9.28 $-1.21 0.00
2020-12-31 8.85 $-1.16 0.00
2020-09-30 11.60 $-0.90 0.00
2020-06-30 26.95 $-0.76 0.00
2020-03-31 7.44 $-0.87 0.00
2019-12-31 3.30 $-1.00 0.00
2019-09-30 2.05 $-1.02 0.00
2019-06-30 2.94 $-1.04 0.00
2019-03-31 3.73 $-1.01 0.00
2018-12-31 4.00 $-0.82 0.00
2018-09-30 5.56 $-0.85 0.00
2018-06-30 3.92 $-0.76 0.00
2018-03-31 4.71 $-0.83 0.00
2017-12-31 4.13 $-0.90 0.00
2017-09-30 6.34 $-0.88 0.00
2017-06-30 7.84 $-0.97 0.00
2017-03-31 6.62 $-0.88 0.00
2016-12-31 6.94 $-0.89 0.00
2016-09-30 9.32 $-0.80 0.00
2016-06-30 9.24 $-0.32 0.00
2016-03-31 8.71 $-0.24 0.00
2015-12-31 6.72 $-0.22 0.00
2015-09-30 5.78 $-0.25 0.00
2015-06-30 8.16 $-0.61 0.00
2015-03-31 8.16 $-0.63 0.00
2014-12-31 9.18 $-0.53 0.00
2014-09-30 9.85 $-0.37 0.00
2014-06-30 10.81 $-0.34 0.00
2014-03-31 13.32 $-0.31 0.00
2013-12-31 11.60 $-0.34 0.00
2013-09-30 8.28 $-0.50 0.00
2013-06-30 3.18 $-0.57 0.00
2013-03-31 2.38 $-0.63 0.00
2012-12-31 2.00 $-0.66 0.00
2012-09-30 2.34 $-0.65 0.00
2012-06-30 1.84 $-0.64 0.00
2012-03-31 2.68 $-0.61 0.00
2011-12-31 1.71 $-0.63 0.00
2011-09-30 2.26 $-0.61 0.00
2011-06-30 2.40 $-0.48 0.00
2011-03-31 4.40 $-0.48 0.00
2010-12-31 4.60 $-0.47 0.00
2010-09-30 5.00 $-0.60 0.00
2010-06-30 4.08 $-0.56 0.00
2010-03-31 5.28 $-0.73 0.00
2009-12-31 4.56 $-0.76 0.00
2009-09-30 6.28 $-0.73 0.00
2009-06-30 3.20 $-1.04 0.00
2009-03-31 1.56 $-1.01 0.00
2008-12-31 2.08 $-1.02 0.00
2008-09-30 2.48 $-0.95 0.00
2008-06-30 4.32 $-0.89 0.00
2008-03-31 3.84 $-0.92 0.00
2007-12-31 3.68 $-1.12 0.00
2007-09-30 5.40 $-0.70 0.00
2007-06-30 11.20 $-0.86 0.00
2007-03-31 12.96 $-0.93 0.00
2006-12-31 13.16 $-0.90 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.477B $0.007B
Inovio Pharmaceuticals, Inc., formerly known as Inovio Biomedical Corporation, is engaged in the discovery, development, and delivery of a new generation of vaccines, called DNA vaccines, focused on cancers and infectious diseases. The Company's electroporation DNA delivery technology uses brief, controlled electrical pulses to increase cellular DNA vaccine uptake. Inovio's clinical programs include human papillomavirus (HPV)/cervical cancer (therapeutic), avian influenza (preventative), hepatitis C virus (HCV) and human immunodeficiency virus (HIV) vaccines. It is advancing preclinical research for a universal seasonal/pandemic influenza vaccine. The Company's partners and collaborators include University of Pennsylvania, National Microbiology Laboratory of the Public Health Agency of Canada, NIAID, Merck, ChronTech, University of Southampton, and HIV Vaccines Trial Network. Inovio Pharmaceuticals, Inc. is headquartered in Blue Bell, Pennsylvania.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.683B 8.63
Bio-Rad Laboratories (BIO.B) United States $21.975B 46.83
QIAGEN (QGEN) Netherlands $11.773B 19.94
Biohaven Pharmaceutical Holding (BHVN) United States $8.738B 0.00
Emergent Biosolutions (EBS) United States $2.722B 6.57
Arcus Biosciences (RCUS) United States $2.455B 0.00
Myovant Sciences (MYOV) United Kingdom $1.915B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.755B 0.00
Zymeworks (ZYME) Canada $1.208B 0.00
Ambrx Biopharma (AMAM) United States $0.470B 0.00
SQZ Biotechnologies (SQZ) United States $0.342B 0.00
Enzo Biochem (ENZ) United States $0.183B 18.00